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Publication No. 
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Supervisory Professor: Mien-Chie Hung, Ph.D 
 
 
ABSTRACT 
Sirtuin6 (SIRT6) is one of the members of the Sirtuin family and functions as a 
longevity assurance gene by promoting genomic stability. It also regulates various 
cancer-associated pathways and was recently established as a bonafide tumor suppressor 
in colon cancer. This suggests that SIRT6 is an attractive target for pharmacological 
activation in cancer treatment, and hence, identification of potential regulators of SIRT6 
would be an important and critical contribution towards cancer treatment. Here, we show 
that AKT1 phosphorylates SIRT6 at Ser338 and induces MDM2-SIRT6 interaction, 
priming SIRT6 for degradation via the MDM2-dependent ubiquitin-proteasome pathway. 
Blocking SIRT6 Ser338 phosphorylation prevents its degradation by MDM2 and results in 
inhibition of cell proliferation and breast cancer tumorigenesis in vivo. In addition, 
knockdown of SIRT6 in trastuzumab-sensitive cells renders them resistant to trastuzumab  
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 whereas overexpression of phosphorylation defective SIRT6 mutant restores trastuzumab 
sensitivity in the resistant cells. Thus, activation or re-expression of SIRT6 has potential 
clinical application to overcome trastuzumab resistance.  
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 CHAPTER 1:  INTRODUCTION 
 
1.1       Sirtuins 
Sirtuins are a family of class III NAD+ dependent deacetylases that are involved 
in lysine deacetylation of a wide variety of substrates including the histones and also in 
ADP-ribosylation. The first sirtuin was initially identified in yeast in 1984 as the Silent 
information regulator (Sir2) gene and it regulated transcriptional silencing of mating-type 
loci, ribosomal DNA and lifespan (1, 2). Their homologues were identified in 
Caenorhabditis elegans in 2001(3) and in Drosophila melanogaster in 2004 (4). There 
are seven sirtuins, Silent Information Regulator (SIRT) (SIRT1-SIRT7) in humans and 
mammals and they have different enzymatic activity, subcellular localization, activity, 
tissue specificity and targets (5). Over the past few years, sirtuins have gained attention as 
important contributors of extended lifespan in both lower and higher level organisms (6, 
7) and also due to their role as a nexus between caloric restriction and longevity (8-11). 
Due to the fact that malfunctions of even a single sirtuin results in a number of 
pathophysiological complications, many pharmaceutical companies have identified 
agents that target sirtuins (12, 13). In addition, resveratrol, a natural flavonoid present in 
red grapes was shown to activate some of the Sirtuins and hence mimicking caloric 
restriction was seen as a cure for cardiovascular disease, type 2 diabetes and even cancer 
(14).  
The sirtuins have a broad range of localization and substrates. The  
localization pattern and some of the key substrates of different sirtuins are summarized in 
Table 1. 
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 Table 1: The localization and activity of sirtuins 
 
 
 
1.2       Sirtuins and cancer 
 The role of some of the sirtuins in cancer is still under debate due to the 
complexity in their functions and diversity of the substrates. SIRT1 has been shown to be 
an oncogene and is upregulated in a number of cancers including breast cancer (15, 16), 
colon cancer (17), prostate cancer (18), pancreatic cancer (19), hepatocellular carcinoma 
(20, 21), acute myeloid leukemia (22), non-melanoma skin cancers (23, 24) and in adult 
T-cell leukemia (25).       
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  SIRT2 has been shown to be a tumor suppressor in gliomas and deletion in 
locus 19q13.2, where SIRT2 is located is often deleted in gliomas (26). SIRT2 expression 
is also reduced in esophageal and gastric adenocarcinomas (27), mammary carcinoma 
and hepatocellular carcinoma (28) and an inactivating mutation has been identified in the 
catalytic domain of SIRT2 in melanomas (29). Moreover, Histone 3 lysine 53(H3K53), 
the substrate of SIRT2 is hyperacetylated in cancer cells (30). However, in acute myeloid 
leukemia cells, SIRT2 is upregulated and associated with increased cell proliferation and 
cell survival (31). 
 SIRT3 is a mitochondrial sirtuin that regulates oxidative stress and 
metabolism (32). Although there is some evidence that SIRT3 might be a tumor 
suppressor, it is still debatable (33) as its levels are reduced in breast cancer (34) and 
hepatocellular carcinoma, but elevated in malignant and lymph node positive breast 
cancer (35). Loss of SIRT3 leads to an increase in reactive oxygen species (ROS), which 
in turn enhances expression of HIF-dependent genes leading to a cancer phenotype (36). 
On the other hand, SIRT3 overexpression inhibited the growth and induced apoptosis in 
hepatocellular carcinoma cells (37). Also SIRT3 is elevated in oral cell carcinomas that 
are resistant to anoikis (38). 
 SIRT6 is one of the better studied sirtuins after SIRT1 with respect to  
cancer. SIRT6 is a tumor suppressor of the pancreas and colon (39). SIRT6 
overexpression has been shown to induce massive apoptosis in a number of cancer cell 
lines but not in normal cell lines (40). The tumor suppressive activity of SIRT6 has been 
attributed to both its deacetylase activity and ADP-ribosyl transferase activity. Histone 3  
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 lysine 56 (H3K56), a substrate of SIRT6 is hyperacetylated in a number of cancers 
including the breast, colon, skin, liver and thyroid (30).  
                          SIRT7 is perceived as an oncogene as its expression is elevated in breast 
cancer including node-positive breast cancers and in thyroid cancer. SIRT7 is important 
for cancer maintenance rather than cancer initiation (41). SIRT7 deacetylates Histone 3 
lysine 18 (H3K18), leading to anchorage independent growth, loss of contact inhibition 
and progression to tumorigenesis (42). 
 
1.3       Sirtuin 6 
 Sirtuin 6 (SIRT6) is a mammalian homologue of the yeast Sir2 protein. The 
SIRT6 gene is localized to chromosome 19p13.3 in humans and consists of 8 exons that 
codes for a 355-amino acid protein (43). SIRT6 is ubiquitously expressed in most of the 
tissues and predominantly localized in the nucleus and is associated with the chromatin 
(44, 45). The catalytic site of SIRT6 is present in the N-terminal extension and is 
essential for its activity and the nuclear localization signal exists between amino acids 
345-351 at the C-terminal. The nuclear localization signal of SIRT6 is required for its 
proper nuclear localization (46, 47). SIRT6 nuclear localization is independent of its 
enzymatic activity (48, 49). 
 SIRT6 has both deacetylase and ADP-ribosyl transferase activities that are 
dependent on NAD+ levels (50). Although SIRT6 is capable of deacetylating a number of 
substrates including H3K9, H3K56, it’s ADP- ribosyl transferase activity is not yet well 
studied and it’s substrates include itself and PARP1(45, 51). SIRT6 also hydrolyses long-
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 chain fatty acyl groups from lysine residues in palmitoyl, myristoyl and butyryl acids 
(52).  
 SIRT6 is regulated positively by SIRT1 under nutritional stress by forming a 
complex with Forkhead Box O3 (FOXO3a) and Nuclear respiratory factor 1 (NRF1) on 
the NRF1-binding sites on SIRT6 promoter (53). P53 also positively regulates SIRT6 
protein levels under normal nutrient availability and leads to SIRT6 upregulation under 
starvation (54). Also, miR-33b overexpression downregulates SIRT6 mRNA and protein 
levels (55, 56).   
 SIRT6-deficient mice are small and exhibit severe metabolic defects including 
reduced levels of serum glucose and IGF-1 and they also develop aging associated 
abnormalities by 2-3 weeks (44). Caloric restriction (CR) leads to increase in SIRT6 
levels in a tissue-specific manner in mice that overexpress SIRT6 (MOSES mice) and the 
increase in SIRT6 levels was due to enhanced protein stability. The MOSES mice are 
protected against diet induced obesity and other metabolic defects (57). Also SIRT6 
overexpression has been shown to extend life span in male mice through inhibition of 
IGF-1 signaling (58). SIRT6 binds to RelA subunit of NF-κB and gets recruited to NF-κB 
target gene promoters, deacetylates H3 Lysine 9 (H3K9) and suppress genes associated 
with aging and thus extends life span (59).   
 SIRT6 negatively regulates HIF1α by binding to it and hence SIRT6 deficient 
cells exhibit increased glycolysis and reduced oxygen consumption, similar to the 
Warburg effect (60). SIRT6 inhibits AKT phosphorylation at residues Ser473 and Thr308 
and the absence of SIRT6 results in enhanced activation of IGF-AKT signaling and hence 
leading to hypoglycemia. SIRT6 deficient mice are more sensitive to insulin and exhibit 
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 increased AKT activation in various organs even without stimulation with insulin. As a 
consequence of AKT hyperactivation in the absence of SIRT6, increase in membrane 
translocation of GLUT1 and GLUT4 were seen in mice leading to enhanced glucose 
uptake (61). SIRT6 interacts with and deacetylates Forkhead box protein O1 (FOXO1) 
leading to its nuclear exclusion and subsequent downregulation of genes involved in 
gluconeogenesis like Glucose-6-phosphatase (G6PC) and phosphoenolpyruvate 
carboxykinase-1 (PCK1) (62). Relatedly, SIRT6 also regulates gluconeogenesis by 
enhancing GCN5 mediated acetylation and inhibition of Peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α) (63). 
 SIRT6-/- cells exhibit chromosomal aberrations like fragmented chromosomes, 
detached centromeres and dysfunctional telomeres (64). SIRT6 repairs DNA double 
strand breaks (DSBs) through both Non-homologues end joining (NHEJ) and 
homologous recombination (HR) and SIRT6 deficiency results in inefficient double 
strand repair and base excision DNA repair pathways (44, 65-67). SIRT6 plays a role in 
DSB repair by regulating C-terminal binding protein (CtBP) interacting protein (CtIP) 
(66) and poly ADP-ribose polymerase 1 (PARP1) (67) and by physically interacting with 
and mobilizing DNA-dependent protein kinase catalytic subunit (DNA-PK) to the sites of 
DSBs (68). SIRT6 also recruits the chromatin remodeler SNF2H to DSBs and 
deacetylates H3K56. Loss of SIRT6 impairs recruitment of SNF2H and hence increases 
sensitivity to genotoxic stress and DNA damage (69).  
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Figure 1. Summary of the functions of SIRT6 
 
 
 
 
1.4       SIRT6 and cancer 
  SIRT6 has been shown to be associated with cancer through its role in regulating 
cellular stress and organismal aging (70) and through inhibition of the shift towards 
anaerobic glycolysis (39). Characteristics of SIRT6 knockout or knockdown cells 
including genomic instability, hyperactive NF-κB signaling (71), aberrant glucose 
homeostasis (72), aneuploidy (73, 74), are common characteristics of cancer cells and as 
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 expected, loss of SIRT6 is observed in a variety of cancers. SIRT6 downregulation in 
human hepatocytes leads to hepatocellular carcinoma (HCC) through upregulation of 
oncogenes such as IGF2. SIRT6 also suppresses HCC by inhibiting the extracellular 
signal-regulated kinase (ERK) pathway (75). SIRT6 acts as a tumor suppressor in 
gliomas by inhibiting the expression of poly(C)-binding protein (PCBP) 2 (PCBP2) by 
deacetylating H3K9Ac (76). SIRT6 expression is downregulated in colon cancer cells 
through FOXO3a (77). SIRT6 mRNA and protein expression were downregulated in the 
advanced stage of head and neck squamous cell carcinoma than in the early stage (78). In 
liver cancers, c-Fos induces SIRT6 expression and in turn SIRT6 represses expression of 
survivin by deacetylating H3K9 and reducing NF-κB activation. Increasing SIRT6 levels 
at the liver cancer initiation stage impairs liver cancer development and SIRT6 
expression was also found to be low in human dysplastic liver nodules (79). SIRT6 
inhibits colon and pancreatic cancers through repression of MYC dependent transcription 
and ribosomal gene expression and SIRT6 was shown to act as tumor suppressor by 
regulating cancer metabolism and glycolysis and it’s loss could lead to tumorigenesis 
even in the absence of oncogene addiction (39). Also downregulation of SIRT6 mRNA 
expression and Sirt6 gene copy number is observed in various human cancers (39). 
Moreover, the locus in which SIRT6 gene is located is prone to high rates of Loss of 
Heterozygosity (LOH) in human breast cancers (80-82).  
 
1.5       Breast cancer and insulin-like growth factor (IGF) /PI3K/AKT signaling 
Breast cancer is the second most common malignancy among women and the 
second leading cause of cancer associated deaths in the US. In 2014, the American 
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 Cancer Society estimates that about 296,980 new cases of breast cancer are expected to 
be diagnosed among US women and around 39,620 US women are expected to die from 
the disease.  
 Breast cancer is a heterogeneous disease and is classified into different subtypes  
according to the hormone receptor expression pattern. The relationship between breast 
cancer and IGF-PI3K/AKT signaling is well studied and documented. AKT is primarily 
activated by IGF signaling in a phosphatidylinositol 3-kinase (PI3K) dependent manner. 
IGF stimulation leads to dimerization of PI3K and subsequently its autophosphorylation 
and activation. AKT is the central downstream effector of PI3K and is activated by 
interaction with PtdIns(3,4,5)P3 and followed by phosphorylation on two key residues, 
Thr308 and Ser473 by Protein Dependent Kinase 1 (PDK1) (83). Activated AKT in turn 
activates a number of downstream substrates by phosphorylating serine/threonine 
residues in the RXRXXS/T motif (84). AKT signaling plays a critical role in malignant 
transformation through activation of numerous downstream substrates via 
phosphorylation including but not limited to I-κB kinase (IKK), cAMP response element-
binding protein (CREB), forkhead family of transcription factors (FOXOs), glycogen 
synthase kinase (GSK-3), p21Cip1 etc. While growth factors and cytokines result in the 
activation of the pathway, phosphatases negatively regulate the PI3K/AKT activity (85-
88). 
Protein kinase B (AKT) regulates a number of cellular processes including cell 
survival, metabolism, cell cycle, transcriptional regulation and protein synthesis (89-91). 
There are three members in the AKT family, AKT1/PKBα, AKT2/PKBβ and 
AKT3/PKBγ and they are coded by three different genes. Although these three AKT 
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 isoforms share high homology, they differ in their biological functions. Disruption of 
AKT1 exhibits growth retardation in mice, while AKT2 depleted mice show normal 
development, but have type II diabetes like syndrome and AKT3 has been shown to be 
required for normal brain development in mice (92-96). AKT/PKB pathway activation is 
seen in a variety of cancers including the breast, ovarian, colon, pancreas etc.(97, 98). 
 
1.6       Relation between IGF/AKT signaling and SIRT6 
SIRT6 negatively regulates IGF/AKT signaling at chromatin level through 
deacetylation of Histone 3 Lysine 9 (H3K9) (99). SIRT6 knockout mice exhibited cardiac 
hypertrophy and these failing hearts showed activation of genes related to the IGF/AKT 
signaling pathway like IGF-1R, IGF-2R, AKT, FOXO1, mTOR, myc and GSK3. 
Coincidentally, chronic AKT activation exacerbates aging induced cardiac hypertrophy 
(100). SIRT6 interacts with c-Jun and inhibits its transcriptional activity. Under 
physiological stress and pathological conditions, when SIRT6 levels are reduced in the 
cells, there is de-repression of c-Jun mediated transcription, thus leading to increase in 
transcription of the IGF-AKT signaling pathway genes that harbor c-Jun binding sites in 
their promoters (101).  
Transgenic male mice overexpressing SIRT6 show 15% increase in lifespan when 
compared to control mice. The observed increase in lifespan was due to the lower levels 
of IGF-AKT pathway related genes in the SIRT6 overexpressing male mice. Insulin and 
insulin-like growth factor (IGF) signaling have also been uniformly shown to regulate life 
span and longevity ranging from worms to mice and mammals (102-104). Mutations in 
insulin receptor DAF-2 or the PI3K AGE-1 in Caenorhabditis elegans extended the life 
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 span by more than 100% in these worms (105-108). Lifespan of female Drosophila 
melanogaster is extended by about 85% by mutating the insulin receptor and the insulin-
receptor substrate (109, 110) and heterozygous Igf1r+/- mice live 26% longer than their 
wild type counterparts (111). SIRT6 also inhibits phosphorylation of AKT at Ser473 and 
Thr308 by inhibition of various upstream molecules including IRS1, IRS2 and insulin 
receptor and hence the absence of SIRT6 leads to enhanced insulin signaling, activation 
of AKT and membrane recruitment of GLUT1 and GLUT4 leading to hypoglycemia in 
mice (61). This suggests an existing converse relationship between AKT and SIRT6 in 
aging and in cardiac hypertrophy. 
 
1.7       Trastuzumab resistance in HER2 overexpressing breast cancers 
 The Epidermal Growth Factor Receptor 2 (ErbB2 or HER2 or Neu) is one of the 
member of the ErbB family of receptor tyrosine kinases and it is overexpressed in around 
25% of human breast cancers (112). On ligand binding, HER2 dimerizes with itself or 
with other members of the ErbB family, which results in the phosphorylation of several 
tyrosine residues within the regulatory domain, hence leading to its activation. HER2 
contributes to oncogenesis through activation of a number of downstream signaling 
pathways including the Ras-Raf-MAPK and the PI3K-AKT pathways (113, 114).  
Trastuzumab or Herceptin is a humanized monoclonal antibody developed by 
Genentech that targets the extracellular region of HER2. Trastuzumab was approved for 
the treatment of HER2 positive breast cancer patients as an adjuvant therapy, in 
combination with chemotherapy (115).  Although trastuzumab had promising initial 
response in the patients, a subset of patients developed primary or de novo resistance and 
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 another subset of patients who responded initially, acquired resistance during the course 
of treatment.   
A number of factors have been shown to contribute to trastuzumab resistance. 
Epitope masking by MUC4 and CD44, in which the binding of trastuzumab to HER2 is 
disrupted, upregulation of HER2 downstream signaling pathways due to mutation or loss 
of PTEN, increased MAPK and PI3K signaling, overexpression of HER ligands such as 
TGF-α, EGF and heregulin and impaired immune-mediated response due to alteration of 
antibody-dependent cell-mediated cytotoxicity (ADCC). 
Several efforts are being undertaken to overcome this issue of acquired resistance, 
including combining trastuzumab with PI3K inhibitors and c-Src inhibitors, which have 
been shown to be effective in reverting resistance to trastuzumab in preclinical settings 
(116, 117). Trastuzumab-DM1 (T-DM1) was recently developed by Genentech, in which 
the antibody is conjugated to a cytotoxic agent mertansine (118) via a thioether linker. 
Phase 1 clinical trial results with T-DM1 showed that the modified drug was effective in 
patients who had progressed on trastuzumab (119). Also, a Phase II study showed that T-
DM1 was effective as a single-agent therapy in metastatic breast cancer patients who had 
progressed in trastuzumab (120). Thus these studies show that HER2 pathway is an 
effective therapeutic target and novel approaches to target this pathway or to overcome 
its signaling mediated effects would be valuable towards disease treatment. 
 
1.8       Hypothesis 
Although the biological functions of SIRT6 have been gradually recognized, its 
upstream regulation that leads to loss of SIRT6 activity or protein levels is not well 
12 
 
 understood. A recent study reported that the phosphorylation of SIRT6 on S338 may 
regulate interactions with a subset of proteins, but no biological consequences of this 
phosphorylation were identified (121). 
Phenotypes of SIRT6-/- mice, including accelerated aging, cardiac hypertrophy, 
and reduced lifespan, are similar to those associated with hyperactivation of the IGF-
AKT pathway (58, 122). Also, studies have indicated that SIRT6 negatively regulates 
IGF-AKT signaling by inhibiting gene transcription and AKT phosphorylation (59, 99). 
As PI3K/AKT signaling pathway is one of the major oncogenic signaling cascades that 
results in tumor growth and development (123-125), we hypothesized that IGF-AKT 
signaling might also regulate SIRT6. If this is the case, identification of novel regulations 
of SIRT6 would be valuable towards the treatment of various metabolic disorders 
including cancer. 
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 CHAPTER 2:   MATERIAL AND METHOD 
 
2.1       Cell lines 
All cell lines used were purchased from the American Type Culture Collection 
(ATCC). They included HEK293T, a HEK cell line; MCF-7, a human mammary 
adenocarcinoma cell line from pleural effusion; MDA-MB-231, a human mammary 
adenocarcinoma cell line from pleural effusion; Hs578T, a human mammary carcinoma 
cell line; and HBL-100, a human mammary epithelial carcinoma. The BT474 (BT474-P) 
cell line and its trastuzumab-resistant counterpart (BT474-TtzmR) were gifts from D. Yu 
at The University of Texas MD Anderson Cancer Center (Houston, TX). All cells were 
grown on tissue culture dishes in Dulbecco’s modified Eagle’s medium/F12 
(DMEM/F12) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 
penicillin and streptomycin (100 U, 100 ng/ml) at 37°C in a humidified atmosphere with 
5% CO2, unless specified otherwise. Before IGF (50 ng/ml) or EGF (50 ng/ml) 
treatment, the cells were serum-starved overnight. The concentrations and treatment 
durations of each chemical were as follows: MK2206 (2 μM, 1 hour), MG-132 (10 μM, 7 
to 10 hours), and cycloheximide (1 μg/ml). Stable puromycin-resistant cell lines were 
maintained in DMEM/F12 medium that contained puromycin (1 μg/ml). 
 
2.2       Antibodies 
Commercial antibodies against SIRT6 (1:1000), AKT1 (1:1000), AKT2 (1:1000), 
AKT3 (1:1000), and phospho-AKT Ser473 (1:1000) were purchased from Cell Signaling 
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 Technology; antibody against phosphorylated SIRT6 Ser338 (1:500) was from Abnova; 
and antibodies against HA (1:2000) and Flag (1:2000) were from Sigma. 
 
2.3       Reagents 
The AKT inhibitor MK2206 was purchased from Selleck Chemicals. MG-132, 
cycloheximide, EGF, and IGF were purchased from Sigma. 
 
2.4       Plasmids 
DNA plasmids encoding Flag-SIRT6 (plasmid 13817), HA-myr-AKT1 (plasmid 
9008), and HA-myr-AKT3 (plasmid 9017) were from Addgene. Wild-type MDM2 and 
the MDM2 deletion mutant (MDM2-Δ9) were gifts from J. Chen (H. Lee Moffitt Cancer 
Center, Tampa, FL). SIRT6-S338A and SIRT6-S338D point mutants were generated 
using the QuickChange Site-Directed Mutagenesis Kit from Stratagene using the 
following primers: SIRT6-S338D, 5′-GCGGCCCACCGACCCTGCCCCCCACAG-3′ 
(forward) and 5′-GTGGGGGGCAGGGTCGGTGGGCCGCTC-3′ (reverse). All 
lentiviral pLKO.1 expression and shRNA-encoding plasmids were purchased from 
Sigma. SIRT6 shRNA 1 clone ID: TRCN0000232532: 
CCGGCTCCCTGGTCTCCAGCTTAAACTCGAGTTTAAGCTGGAGACCAGGGAG
TTTTTG; SIRT6 shRNA 2 clone ID: 
TRCN0000050473:CCGGTGGAAGAATGTGCCAAGTGTACTCGAGTACACTTGG
CACATTCTTCCATTTTTG.Wild-type MDM2 and MDM2 deletion mutants were gifts 
from J. Chen (H. Lee Moffitt Cancer Center, Tampa, FL). AKT1, AKT2, and MDM2 
siRNAs were purchased from Sigma. 
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 2.5       Immunoblotting, immunoprecipitation, and ubiquitination assays 
Immunoblotting, immunoprecipitation, and ubiquitination assays were performed 
as previously described (124), using antibodies against SIRT6, AKT1, AKT2, 
phosphorylated AKT at Ser473 (Cell Signaling Technology), tubulin, and actin (Sigma). 
For glutathione S-transferase (GST) pull-down assays, GST-SIRT6 protein (10 μg) was 
incubated with 2 mg of MCF-7 cell extract overnight at 4°C. GST-tagged proteins were 
recovered by incubating the reaction mixture with 20 μl of glutathione Sepharose beads at 
4°C overnight. The bead pellet was washed three times in 1X phosphate-buffered 
saline. The boiled samples were then subjected to 10% SDS–polyacrylamide gel 
electrophoresis (SDS-PAGE). 
 
2.6       In vitro kinase assay 
Purified GST-SIRT6 (wild-type or mutant) fragments were incubated with active 
AKT1 (Millipore) and 50 mM ATP (adenosine 5′-triphosphate) in a kinase buffer 
containing [32P] ATP (5 μCi) for 30 min at 30°C. The reaction products were resolved via 
SDS-PAGE, and 32P-labeled products were detected using autoradiography. 
 
2.7       Identification of phosphorylation sites by mass spectrometry analysis 
HeLa cell lysates were immunoprecipitated with an antibody against SIRT6 to 
identify the phosphorylation sites of SIRT6 in cells. In vitro, the phosphorylation site of 
SIRT6 was identified using an in vitro kinase assay with recombinant, active AKT1 
kinase and full-length GST-SIRT6. After protein gel electrophoresis, the bands were 
excised and subjected to digestion with trypsin. The enriched phosphopeptides were 
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 isolated using immobilized metal affinity chromatography and analyzed by micro–liquid 
chromatography–tandem mass spectrometry using an UltiMate Capillary LC system (LC 
Packings) coupled to a QSTAR XL quadruple time-of-flight mass spectrometer (Applied 
Biosystems). The product ion spectra, generated by nanoscale capillary spectrometry, 
were searched against National Center for Biotechnology Information databases for exact 
matches using the ProID (Applied Biosystems) and MASCOT search programs. 
Carbamidomethyl cysteine was set as a fixed modification, and serine, threonine, and 
tyrosine phosphorylation were set as variable modifications. All phosphopeptides 
identified were confirmed by manual interpretation of the spectra. 
 
2.8       Cell growth, soft agar, and cell viability assays 
Cell growth was determined by cell counting. Cells (1 × 105) were plated in 
triplicate in 12-well plates. They were then trypsinized at the indicated time points and 
counted. For the soft agar transformation assay, 2.5 × 104 cells were seeded in 1 ml of 
DMEM with 10% FBS and 0.4% agarose and overlaid on 1 ml of DMEM with 10% FBS 
and 0.8% agarose in each well of a six-well plate. After 2 to 3 weeks, colonies larger than 
2 mm in diameter were counted. 
 
2.9       Animal studies 
MDA-MB-231 cells (2 × 106) with lentiviral-stable expression of SIRT6-WT, 
SIRT6-S338A, or SIRT6-S338D and Sh SIRT6 or Sh Luc control cells were injected into 
the mammary fat pads of nude mice (five per group). Tumor size was measured every 3 
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 days with a caliper, and tumor volume was determined using the formula L × W2 × 0.52, 
where L is the longest diameter and W is the shortest diameter. All animal procedures 
were conducted under regulations of Division of Laboratory Animal Medicine at The 
University of Texas MD Anderson Cancer Center. Animal protocols (protocol number 
06-87-06139) were reviewed and approved by the Institutional Animal Care and Use 
Committee at The University of Texas MD Anderson Cancer Center. 
 
2.10       Breast tumor tissue specimens 
One hundred twenty-six formalin-fixed and paraffin-embedded infiltrating breast 
carcinoma patient samples were obtained from the Department of Pathology, Shanghai 
East Breast Disease Hospital, and People’s Republic of China. Breast cancer tissue 
microarray containing 186 cases was purchased from Pantomics (BRC2281). 
 
2.11       Immunohistochemical staining 
A modified immunoperoxidase staining was used as described previously (126) 
for staining with SIRT6 (Novus, NB100-2522), phospho-AKT Ser473 (Cell Signaling 
Technology, 3787S), and phospho-SIRT6 (Bioss, bs-5634R-bio). 
 
2.12       Statistical analysis 
SAS software (version 8.1) was used for the statistical analysis (SAS Institute). 
A univariate analysis was used to determine the variable distributions. Categorical 
variables among the groups were compared using the χ2 test or Fisher’s exact test if 20% 
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 of the expected values were less than 5. Continuous variables were analyzed using 
Student’s t test. A P value <0.05 was considered statistically significant. 
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 CHAPTER 3:  SIRT6 IS DOWNREGULATED BY AKT1 
 
3.1       Activation of AKT1 promotes SIRT6 degradation 
To determine whether AKT signaling regulates SIRT6 expression, AKT1 and 
AKT2 were knocked down by silencing RNA [small interfering RNA (siRNA)] in MCF-
7 (Figure. 2, A and B) and MDA-MB-231 (Figure. 2C) human breast cancer cells. Only 
knockdown of AKT1, but not AKT2, resulted in significant increase in SIRT6 protein 
abundance. We also observed increased reduction in the endogenous SIRT6 protein 
abundance with overexpression of constitutively active AKT1 in MDA-MB-231 cells 
(Figure. 3A) and exogenous SIRT6 abundance in human embryonic kidney (HEK) 293T 
cells (Figure. 3B). Overexpression of constitutively active AKT3 did not decrease SIRT6 
protein abundance (Figure. 3C), indicating that AKT1 may be the dominant kinase that 
regulates SIRT6 abundance. Thus, we focused on AKT1 for further experiments. Adding 
MK2206, an AKT inhibitor, to cultures increased the abundance of SIRT6 in MCF-7, 
MDA-MB-231, and two additional breast cancer cell lines, HBL-100 and Hs578T 
(Figure. 4). Treatment with growth factors, such as epidermal growth factor (EGF) and 
IGF activated AKT1 and decreased SIRT6 abundance in a time-dependent manner 
(Figure. 5). Furthermore, only the expression of constitutively active, but not the 
dominant negative, kinase-deficient AKT1 decreased the abundance of Flag-tagged 
SIRT6 in HEK293T cells (Figure. 6). Thus these results suggest an inverse correlation 
between AKT activation and SIRT6 abundance and that the kinase activity of AKT1 is 
required for SIRT6 degradation. 
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 Figure 2: AKT activation promotes SIRT6 degradation 
 
A. Western blotting for SIRT6 and AKT1 against tubulin (loading control) in lysates  
from MCF-7 cells transfected with one of two siRNAs against AKT1 
      
                                
 
B. Western blotting for SIRT6 and AKT2 against tubulin (loading control) in lysates  
from MCF-7 cells transfected with one of two siRNAs against AKT2 
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 Figure 2: AKT activation promotes SIRT6 degradation 
 
C. Western blotting for SIRT6, AKT1 and AKT2 against tubulin (loading control) in 
      lysates from MDA-MB-231 cells transfected with siRNAs against AKT1 and AKT2 
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 Figure 3: AKT1 but not AKT2 and AKT3 degrades SIRT6 
 
A. Western blotting for SIRT6 or HA in lysates from MDA-MB-231 cells transfected 
with 2 or 6 μg of HA-tagged, constitutively active AKT1 (HA-myr-AKT1) or a control 
vector (−) 
                            
 
B. Western blotting for the Flag and the HA tag in lysates from HEK293T cells 72  
hours after transfection with HA-tagged constitutively active AKT1 (HA-myr-AKT1) 
along with Flag-tagged SIRT6. 
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 Figure 3: AKT1 but not AKT2 and AKT3 degrades SIRT6 
 
C. Western blotting for the Flag and the HA tag in lysates from HEK293T cells 72  
hours after transfection with HA-tagged constitutively active AKT3 (HA-myr-AKT3) 
along with Flag-tagged SIRT6. 
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 Figure 4: Inhibition of AKT with an inhibitor rescues SIRT6 levels 
 
Western blotting for SIRT6 or phosphorylated AKT (pAKT-Ser473) in lysates 
from  MCF-7, MDA-MB-231, HBL100 and Hs578T cells treated with 2 μM MK2206 
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 Figure 5: Activation of AKT with growth factors results in SIRT6 degradation 
 
Western blotting for SIRT6 or phosphorylated AKT (pAKT-Ser473) in lysates from MCF-
7, MDA-MB-231 and Hs578T cells treated with IGF (50 ng/ml) for the indicated time. 
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 Figure 6: Kinase activity of AKT is required for SIRT6 degradation 
 
Western blotting in lysates from HEK293T cells transfected with HA-tagged dominant 
negative AKT1 (DN-HA-AKT1) or constitutively active AKT1 (HA-myr-AKT1; “CA”) 
and Flag-tagged, wild type (WT) SIRT6. 
 
                                    
 
3.2      Inverse correlation between AKT activation and SIRT6 levels in human 
breast cancers 
To further study the observed inverse correlation between AKT activation and 
SIRT6 abundance, we stained for SIRT6 and AKT phosphorylated at Ser473 in a panel of 
breast cancer cell lines (Figure. 7A) and 312 patient breast tumor tissue specimens (126 
paraffin-embedded samples and 186 samples from tissue microarray) (Figure. 7B and 
Table 2). In concert with the cell line data, we observed a negative correlation between 
SIRT6 levels and that of phospho-AKT-Ser473 in human breast cancers. 
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 3.3      AKT1 promotes SIRT6 degradation in a proteosome dependent manner 
To determine whether AKT1-mediated SIRT6 suppression was because of 
changes in protein stability, we measured the half-life of a Flag-tagged SIRT6 in 
HEK293T cells that overexpressed hemagglutinin (HA)–tagged, constitutively active 
AKT1. The half-life of SIRT6 was shorter in the presence of active AKT1 than it was in 
the presence of the vector (Figure. 8A), prompting us to examine whether this decrease 
was the result of 26S proteasome–mediated degradation. Pretreating HEK293T cells with 
the proteasome inhibitor MG-132 or the AKT inhibitor MK2206 rescued AKT1-induced 
suppression of SIRT6 abundance (Figure. 8B). Additionally, overexpression of AKT1 
enhanced the ubiquitination of SIRT6 in the presence of MG-132, which was inhibited by 
either MK2206 or wortmannin, a PI3K inhibitor (Figure. 8C). Together, these results 
suggest that SIRT6 protein abundance is suppressed in a proteasome-dependent manner, 
and this is dependent on the kinase activity of AKT1. 
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 Figure 7: Inverse correlation between AKT activation and SIRT6 levels in Breast 
Cancers 
 
A. Western blotting for SIRT6 and phosphorylated AKT in lysates from a panel of breast 
cancer cell lines. 
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 Figure 7:  Correlation between pAKT-Ser473 and SIRT6 levels in Breast Cancers 
 
B. Immunohistochemical analysis of the abundance of phosphorylated AKT (Ser473) 
and SIRT6 in tumor sections from two different breast cancer patients (cases 1 and 2). 
Scale bars, 25 μm. 
                           
 
Table 2: Correlation between phospho-AKT Ser473 and SIRT6 in breast cancer. 
 
The correlation was studied in an array of 186 human breast cancers and 126 formalin fixed and 
paraffin-embedded breast carcinoma patient samples, analyzed using χ2 test (P = 0.024) 
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 Figure 8: AKT1 promotes SIRT6 degradation in a proteosome dependent manner 
 
A. Western blotting in lysates from HEK293T cells transfected with Flag-tagged SIRT6 
and either vector or HA-AKT1 in the presence of cycloheximide (CHX) for up to 8 
hours. Short Exp- shorter exposure time. 
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 Figure 8:  AKT1 promotes SIRT6 degradation in a proteosome dependent manner 
 
B. Western blotting in lysates from HEK293T cells transfected with constitutively active  
AKT1 or Flag-tagged SIRT6 and treated with either MG-132 or MK2206 (AKTi). 
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 Figure 8:  AKT1 promotes SIRT6 degradation in a proteosome dependent manner 
 
C. Western blotting (WB) for ubiquitin and SIRT6 after immunoprecipitation (IP) for  
SIRT6 in lysates from HEK293T cells transfected with HA-myr-AKT1 then treated with 
either MK2206 or PI3K inhibitor Wortmannin for 1 hour and MG-132 for 7 hours 
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 CHAPTER 4:   AKT1 INTERACTS WITH AND PHOSPHORYLATES SIRT6 
 
4.1      AKT1 interacts with SIRT6 
 To explore the mechanism of how AKT1 mediates the suppression of SIRT6, we 
first characterized the interaction between the two proteins. Both endogenous SIRT6 
(Figure. 9A) and exogenous Flag-tagged SIRT6 (Figure. 9B) physically associated with 
AKT1 in an immunoprecipitation assay. In addition, endogenous AKT1 interacted with 
endogenous SIRT6, as shown by reciprocal immunoprecipitation (Figure. 9C). 
 
 
Figure 9: AKT1 interacts with SIRT6 
 
A. Immunoprecipitation (IP) for SIRT6 followed by immunoblotting in lysates from 
MCF-7 cells against an IgG (immunoglobulin G) control. 
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 Figure 9: AKT1 interacts with SIRT6 
 
B. Lysates of HEK293T cells that were transfected with Flag-tagged SIRT6 and HA  
tagged AKT1 were immunoprecipitated with a Flag antibody and immunoblotted for 
SIRT6 and AKT1. 
 
                  
 
 
C. Immunoprecipitation (IP) for AKT1 followed by immunoblotting in lysates from  
MCF-7 cells against an IgG (immunoglobulin G) control. 
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 4.2      AKT1 phosphorylates SIRT6 on Ser338 
  In order to investigate if AKT1 phosphorylates SIRT6, we performed an in vitro 
kinase assay, which showed that full-length recombinant SIRT6 could be directly 
phosphorylated by recombinant, functionally active AKT1 (Figure. 10). To further 
identify the AKT1-mediated phosphorylation sites on SIRT6, we isolated SIRT6 from 
cells treated with EGF or IGF in the presence of MG-132 and analyzed it by mass 
spectrometry. 
 Three phosphorylation sites were identified on SIRT6: Ser303, Ser330, and Ser338 
(Figures. 11A, 11B and 11C). To determine which site (or sites) is phosphorylated by 
AKT1, we mutated each one to an alanine residue and subjected all three mutants to in 
vitro kinase assays. Of these three mutants, phosphorylation was abolished in S338A 
(Figure. 12), suggesting that AKT1 specifically phosphorylates SIRT6 at this position. To 
validate whether this site is phosphorylated in cells, we used a commercially available 
antibody that recognizes SIRT6 phosphorylated at Ser338 and, thus, detected Flag-tagged 
wild-type but not the nonphosphorylatable S338A mutant SIRT6 in MDA-MB-231 cells 
(Figure. 13A). Moreover, in serum-starved MDA-MB-231 cells treated with IGF-1 for 1 
hour in the presence of the protease inhibitor MG-132 to stabilize protein abundance, we 
observed an increase in SIRT6 phosphorylation at Ser338 (Figure. 13B). A search of the 
National Center for Biotechnology Information database using the Basic Local 
Alignment Search Tool (BLAST) revealed that Ser338 of SIRT6 is highly conserved 
among mammals (Figure. 14). It should be noted that Ser338 residue was also identified 
recently by another independent group (127). Together, these results support that Ser338 
of SIRT6 is an AKT1 phosphorylation site. 
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 Figure 10: AKT1 phosphorylates SIRT6 
 
In vitro kinase assay with recombinant, active AKT1 and recombinant GST-tagged, full-
length WT SIRT6 
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 Figure 11: Three phosphorylation sites identified on SIRT6 
 
Mass spectrometry analysis of lysates from HeLa cells that had been serum-starved 
overnight, stimulated with EGF (50 ng/ml) for 30 min, and subjected to 
immunoprecipitation with a SIRT6 antibody identified three phosphorylation sites on 
SIRT6 
A.   Ser303 
               
B.   Ser330 
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 Figure 11: Three phosphorylation sites identified on SIRT6 
 
C.   Ser338 
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 Figure 12: AKT1 phosphorylates SIRT6 on Ser338 
 
In vitro kinase assay with recombinant, active AKT1 and either recombinant GST-
tagged, full-length WT or mutant SIRT6. pSIRT6: phosphorylated SIRT6; 
GSK3: control AKT substrate. 
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 Figure 13: SIRT6 is phosphorylated on Ser338 
 
A. Immunoblot for phosphorylated SIRT6-Ser338 (pSIRT6-Ser338) in MDA-MB-231 
cells that stably express Flag-tagged WT or mutant (S338A) SIRT6, demonstrating 
specificity of the antibody. 
                                         
 
B. Western blots for phosphorylated SIRT6 or AKT in lysates from MDA-MB-231 cells 
serum-starved overnight and then treated with IGF-1 in the presence of MG-132 
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 Figure 14: AKT1 phosphorylation site on SIRT6 is conserved 
 
Sequence alignment of the AKT1 phosphorylation motif of SIRT6 from various species. 
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 CHAPTER 5:  MDM2 is required for AKT1-mediated SIRT6 degradation 
 
5.1       MDM2 overexpression leads to SIRT6 degradation 
MDM2 is the most well-characterized oncogenic E3 ligase in the PI3K-AKT 
pathway and is phosphorylated and activated by AKT (128) (129). Because AKT1 
suppresses SIRT6 protein abundance by decreasing its stability, we investigated whether 
MDM2 is involved in this process.  
First, we found that overexpression of wild-type MDM2, but not the MDM2-Δ9 
mutant, which lacks its E3 ligase domain (130), reduced endogenous SIRT6 abundance in 
HEK293T cells (Figure. 15A). In MCF-7 cells, the abundance of SIRT6 increased when 
MDM2 was knocked down by siRNA (Figure. 15B). In addition, when ubiquitin was 
overexpressed concomitantly with MDM2 in HEK293T cells in the presence of MG-132, 
we observed a polyubiquitination pattern of SIRT6 (Figure. 16), suggesting that SIRT6 
may be polyubiquitinated for subsequent proteasome degradation. 
 
5.2       MDM2 interacts with SIRT6 and subjects it to proteosome-mediated 
degradation 
 Immunoprecipitation showed that MDM2 interacted with endogenous SIRT6 in 
MCF-7 cells (Figure. 17A) and with exogenous Flag-SIRT6 in HEK293T cells (Figure. 
17B). We then analyzed the half-life of SIRT6 by using the protein synthesis inhibitor 
cycloheximide. Similar to the observations of SIRT6 abundance in HEK293T cells 
overexpressing a constitutively active AKT1 in the presence of MG-132 (Figure. 8B), 
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 exogenous SIRT6 abundance decreased by 50% in the presence of MDM2 after 4 hours 
in the presence of cycloheximide, whereas MG-132 prevented the degradation of SIRT6 
even after 8 hours (Figure. 18). Furthermore, SIRT6 could no longer be suppressed by 
IGF stimulation when MDM2 is knocked down by siRNA in MCF-7 cells (Figure. 19). 
These results suggest that MDM2 degrades SIRT6 in a proteasome dependent manner 
and is required for AKT1-mediated SIRT6 degradation. 
 
Figure 15: MDM2 promotes SIRT6 degradation 
 
A. Western blotting in lysates from HEK293T cells transfected with 5 or 10 μg of HA- 
tagged MDM2-WT and MDM2-Δ9 or a control vector. 
   
                              
 
 
 
 
 
 
45 
 
 Figure 15: MDM2 promotes SIRT6 degradation 
 
B. Western blotting in lysates from MCF-7 cells transfected with one of two siRNAs  
against MDM2 or a control siRNA for 72 hours. 
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 Figure 16: MDM2 induces polyubiquitination of SIRT6 
 
Immunoprecipitation (IP) for SIRT6 followed by immunoblotting for ubiquitin (Ub) in 
lysates from HEK293T cells transfected with the indicated plasmids in the presence of 
MG-132 (10 μM for 7 hours). 
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 Figure 17: MDM2 interacts with SIRT6 
 
A. Immunoprecipitation for MDM2 followed by immunoblotting for SIRT6 and MDM2 
in lysates from MCF-7 cells. Short Exp, shorter exposure time. 
 
                                   
 
B. Immunoprecipitation for Flag followed by immunoblotting (WB) in lysates from  
HEK293T cells transfected with HA-tagged WT MDM2 (MDM2-WT) and Flag-tagged 
WT SIRT6 (Flag-SIRT6). 
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 Figure 18: MDM2 degrades SIRT6 in a proteosome dependent manner 
 
Western blotting in lysates from HEK293T cells transfected with WT MDM2 (MDM2-
WT) and Flag-tagged SIRT6 with or without MG-132, in the presence of cycloheximide 
(CHX) for up to 8 hours.               
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 Figure 19: MDM2 is required for AKT mediated SIRT6 degradation 
 
Western blotting in lysates from MCF-7 cells transfected with an siRNA against MDM2 
or a control siRNA for 48 hours, serum-starved for 16 hours, and then cultured with or 
without IGF (50 ng/ml) for 1 hour. 
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 CHAPTER 6:   Phosphorylation of SIRT6 by AKT1 facilitates MDM2-mediated 
degradation 
 
6.1       Phosphorylation of SIRT6 is a prerequisite for MDM2-mediated degradation 
To further show that the phosphorylation of SIRT6 by AKT1 alters its stability, 
we compared the stability of two SIRT6 mutant proteins: SIRT6-S338A, a 
nonphosphorylatable mutant, and SIRT6-S338D, a phosphorylation-mimic mutant. Under 
cycloheximide treatment in MCF-7 cells, the abundance of SIRT6-S338D decreased after 
2 hours, whereas SIRT6-S338A abundance remained unsubstantially changed for at least 
up to 8 hours (Figure. 20A). Consistently, the SIRT6-S338D mutant interacted more 
strongly with MDM2 in MCF-7 cells than did SIRT6-S338A (Figure. 20B). These results 
suggest that AKT1-induced phosphorylation of SIRT6 may recruit MDM2 and 
ubiquitinate SIRT6 to promote its subsequent degradation. To determine whether this 
interaction indeed promoted SIRT6 degradation, the SIRT6-S338A or SIRT6-S338D 
mutant was cotransfected with MDM2 into HEK293T cells. As expected, the abundance 
of SIRT6-S338D, but not SIRT6-S338A, was decreased in the presence of MDM2 
(Figure. 20C). Compared with wild-type SIRT6, the SIRT6-S338D mutant was heavily 
ubiquitinated and the SIRT6-S338A mutant was the least ubiquitinated in the presence of 
MDM2 and MG-132 in MCF-7 cells (Figure. 20D). Together, these data indicate that 
MDM2 is the E3 ligase that mediates SIRT6 degradation and that the interaction between 
MDM2 and SIRT6 is dependent on AKT1-mediated SIRT6 phosphorylation on Ser338. 
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 Figure 20: Phosphorylation of SIRT6 by AKT1 facilitates MDM2-mediated 
ubiquitination and degradation 
 
A.  SIRT6-S338A mutant is stable than the SIRT6-S338D mutant 
Western blotting in lysates from MCF-7 cells that stably express Flag-tagged SIRT6-
S338A (Flag-SIRT6-A) or SIRT6-S338D (Flag-SIRT6-D) in the presence of 
cycloheximide (CHX) for up to 8 hours. 
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 Figure 20: Phosphorylation of SIRT6 by AKT1 facilitates MDM2-mediated 
degradation 
 
 B.   SIRT6-S338D mutant interacts strongly with MDM2 
Immunoprecipitation (IP) with a Flag antibody followed by immunoblotting (WB) in 
lysates from MCF-7 cells that stably express Flag-tagged, WT SIRT6 (WT), SIRT6-
S338A (A), or SIRT6-S338D (D) treated with MG-132 for 7 hours. 
                       
 
C.    SIRT6-S338D but not SIRT6-S338A mutant is degraded by MDM2 
Western blotting in lysates from HEK293T cells transfected with Flag-tagged SIRT6-
S338A (Flag-SIRT6-S338A) or Flag-tagged SIRT6-S338D (Flag-SIRT6-S338D) and 
WT MDM2, harvested 72 hours after transfection. 
                             
53 
 
 Figure 20: Phosphorylation of SIRT6 by AKT1 facilitates MDM2-mediated 
degradation 
 
D.   SIRT6-S338D mutant is highly ubiquitinated 
Immunoprecipitation with a Flag antibody followed by immunoblotting for ubiquitin in 
lysates from HEK293T cells transfected with either Flag-tagged WT SIRT6 (Flag-
SIRT6-WT) or mutant SIRT6 (S338A or S338D) and WT MDM2 and ubiquitin (Ub) and 
treated with MG-132 for 7 hours. 
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 CHAPTER 7:   Nonphosphorylatable SIRT6 inhibits breast cancer tumorigenesis   
 
7.1       Nonphosphorylatable SIRT6 inhibits breast cancer tumorigenesis 
Because the nonphosphorylatable SIRT6 mutant had enhanced stability and the 
phosphorylation-mimic mutant had less stability compared to the wild-type SIRT6, we 
examined the function of SIRT6-WT, SIRT6-S338A, and SIRT6-S338D in cellular 
proliferation and breast cancer tumorigenesis. Knockdown of endogenous SIRT6 by short 
hairpin RNA (shRNA) increased the proliferation of MDA-MB-231 cells in culture, as 
determined by a cell counting assay (Figure. 21A), and enhanced the growth of MDA-
MB-231 xenografts in the mammary fat pads of nude mice (Figure. 21B). We further 
examined the function of the phosphorylation of SIRT6 at Ser338 in cell proliferation and 
tumorigenesis by expressing wild-type or either mutant SIRT6 in MDA-MB-231 cells. 
Expression of the nonphosphorylatable SIRT6-S338A mutant suppressed cell 
proliferation (Figure. 21C) and colony formation on soft agar (Figure. 21D) more than 
the wild-type SIRT6 or the phosphorylation-mimic SIRT6-S338D mutant compared to 
the vector control.  
To further test the tumor-suppressive activity of SIRT6 mutants in vivo, we 
injected MDA-MB-231 cells stably expressing the control vector, wild-type SIRT6, or 
either mutant SIRT6 into the mammary fat pads of nude mice and monitored tumor 
development. We found that tumor volume in mice injected with MDA-MB-231 cells 
stably expressing wild-type SIRT6 was smaller than those injected with cells expressing 
the control vector. The growth of tumors expressing the SIRT6-S338A mutant was 
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 significantly decreased compared with those expressing the control vector or the 
phosphorylation-mimic SIRT6-S338D mutant (Figure. 21E). 
To further investigate whether the expression of SIRT6 phospho-mutants affects 
the endogenous expression of known SIRT6 target genes that are involved in promoting 
tumorigenesis, we performed a quantitative reverse transcription polymerase chain 
reaction (RT-PCR) analysis of MDA-MB-231 cells expressing vector control, SIRT6-
WT, SIRT6-S338A,or SIRT6-S338D. We found that the SIRT6-S338A mutant 
suppressed the mRNA abundance of a panel of target genes more significantly (AKT1, 
AKT3, IGF-1R, PDK1, MTOR, and LDHA) than others (GSK3B and PFKM), whereas 
the SIRT6-S338D mutant had no inhibitory effect on the target genes compared to 
SIRT6-WT (Figure. 22A). SIRT6-deficient mice exhibit increased phosphorylation of 
AKT compared with controls and subsequently have severe hypoglycemia because of 
enhanced basal and insulin-stimulated glucose uptake (131). On the other hand, SIRT6-
deficient mouse embryonic fibroblasts (MEFs) showed similar amounts of 
phosphorylated AKT to wild-type MEFs (132) . Thus, we investigated the 
phosphorylation of AKT in MDA-MB-231 breast cancer cell line that expressed vector, 
SIRT6-WT, A-SIRT6, or D-SIRT6. Clones were chosen in such a way that the 
expression of wild-type and mutant SIRT6 were similar, which would make the 
phosphorylation of AKT comparable. In our system, although there was a slight decrease 
in the abundance of phosphorylated AKT in the presence of wild-type SIRT6 as 
previously reported (131) , there was no significant difference between the mutants and 
the wild-type SIRT6 (Figure. 22B), suggesting that the Ser338 mutation on SIRT6 might 
not contribute to SIRT6-mediated suppression of AKT activation. 
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 Figure 21: Nonphosphorylatable SIRT6 inhibits breast cancer tumorigenesis 
 
A. Proliferation and immunoblot of MDA-MB-231 cells transfected with either shRNA 
against luciferase or one of two shRNAs against SIRT6. Data are means ± SE from three 
experiments. 
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 Figure 21: Nonphosphorylatable SIRT6 inhibits breast cancer tumorigenesis 
 
B. Growth of mammary fat pad xenografts derived from MDA-MB-231 cells transfected  
with either luciferase shRNA or one of two SIRT6 shRNAs. Data are means ± SE from 
five mice per group. 
                                              
 
 
C. Proliferation and immunoblot of MDA-MB-231 cells infected with lentiviral vector, 
WT SIRT6 (SIRT6-WT), SIRT6-S338A, or SIRT6-S338D. Data are means ± SE from 
three experiments. 
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 Figure 21: Nonphosphorylatable SIRT6 inhibits breast cancer tumorigenesis 
 
D. Soft agar colony formation by MDA-MB-231 cells infected with lentiviral vector, 
SIRT6-WT, SIRT6-S338A (SIRT6-A), or SIRT6-S338D (SIRT6-D). 
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 Figure 21: Nonphosphorylatable SIRT6 inhibits breast cancer tumorigenesis 
 
E. Tumor growth of orthotopically transplanted MDA-MB-231 cells infected with  
lentiviral vector, SIRT6-WT, SIRT6-S338A, or SIRT6-S338D. Data are means ± SE 
from five mice per group. 
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 Figure 22: SIRT6 phosphorylation affects expression of endogenous SIRT6 target 
genes, but not AKT phosphorylation 
 
A. Quantitative RT-PCR analysis cDNA was isolated from MDA-MB-231 cells infected  
with lentivirus expressing vector, wild-type (WT) SIRT6, or mutant [S338A (A) or 
S338D (D)] SIRT6. Data are means ± S.E. from 3 experiments;  
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 Figure 22: SIRT6 phosphorylation affects expression of endogenous SIRT6 target 
genes, but not AKT phosphorylation 
 
B. Western blotting for Flag and phosphorylated AKT in MDA-MB-231 cells infected  
with lentivirus expressing vector, Flag-tagged wild-type SIRT6 (SIRT6-WT), or Flag-
tagged SIRT6 mutant [S338A (Flag-SIRT6-A) or S338D (Flag SIRT6-D)]. Blot is 
representative; data are means ± S.E. from 3 experiments. 
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 7.2       High SIRT6 levels correlate with better prognosis in breast cancer patients 
To determine the correlation between SIRT6 phosphorylation and breast cancer 
patient survival or disease progression, immunohistochemical staining was performed for 
total and phosphorylated SIRT6 in biopsy tissues from 126 breast cancer patients. 
Patients whose tumors had high SIRT6 abundance had better overall survival than those 
whose tumors had low SIRT6 abundance. However, patients whose tumors had high 
abundance of phosphorylated SIRT6 had poorer overall survival than those whose tumors 
had low abundance of phosphorylated SIRT6 (Figure. 23A and 23B). These results 
suggest that SIRT6 and its phosphorylation status may have the potential to be predictive 
of breast cancer patient survival. 
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 Figure 23: High SIRT6 levels correlate with better prognosis in breast cancer 
patients 
 
A. Survival curves of patients with breast tumors that have high or low 
abundance of total or phosphorylated SIRT6. 
 
                                  
 
                                 
 
64 
 
 Figure 23: High SIRT6 levels correlate with better prognosis in breast cancer 
patients 
 
B.  Immunohistochemistry for SIRT6 and phosphorylated SIRT6 in representative 
tumor tissues from patients in (F). +++, high expression; − & +, low or no expression. 
Scale bars, 25 μm. 
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 CHAPTER 8:   Loss of SIRT6 results in trastuzumab resistance in HER2 
overexpressing breast cancer cells. 
 
8.1       Loss of SIRT6 results in trastuzumab resistance in HER2 overexpressing 
breast cancer cells. 
Trastuzumab is a standard treatment for patients with HER2-positive breast 
cancer. However, intrinsic or acquired resistance to this treatment is observed (133, 134). 
Increased or constitutive activation of AKT appears to be a key factor in trastuzumab 
resistance (135-138). Because we found that AKT1 decreased SIRT6 stability through 
phosphorylation and subsequent proteasome-dependent degradation, we speculated that 
SIRT6 might also play a role in trastuzumab resistance. Indeed, SIRT6 abundance was 
lower in two trastuzumab-resistant, HER2-positive breast cancer cell lines (BT474-
TtzmR and SKBR3-TtzmR) compared with trastuzumab-sensitive parental lines 
(BT474-P and SKBR3-P) (Figure. 24A). The abundance of SIRT6 increased after the 
addition of trastuzumab in BT474-P, but not in BT474-TtzmR, cells (Figure. 24B). In the 
BT474-P cells, 24-hour treatment with trastuzumab inhibited the phosphorylation of 
AKT at Ser473, whereas in the BT474-TtzmR cells, there was residual phosphorylation of 
AKT even after 48 hours of trastuzumab treatment. This persistent activation of AKT 
appeared to attenuate the increase in SIRT6 protein abundance seen in the parental cells, 
suggesting that the induction of SIRT6 contributes to the therapeutic effect of 
trastuzumab. To further validate the above findings, we knocked down SIRT6 in 
BT474-P cells and cultured them in trastuzumab for 4 days. Loss of SIRT6 in 
trastuzumab-sensitive BT474-P cells decreased cell sensitivity to trastuzumab to a similar 
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 sensitivity seen in BT474-TtzmR cells as measured by relative metabolic activity in an 
MTT assay (Figure. 24C). Expression of the nonphosphorylatable SIRT6-S338A mutant 
considerably resensitized BT474-TtzmR cells to trastuzumab compared with expression 
of either wild-type SIRT6 or the phosphorylation-mimic SIRT6-S338D mutant (Figure. 
24C). These data suggest a mechanism by which trastuzumab inhibits breast cancer cell 
proliferation through the induction of SIRT6 and that loss of SIRT6 mediated by AKT1 
and MDM2 contributes to trastuzumab resistance.  
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 Figure 24: Loss of SIRT6 results in Trastuzumab resistance 
 
A. Western blotting in cell lysates from BT474 parental (BT474-P), BT474 trastuzumab  
resistant (BT474-TtzmR), SKBR3 parental (SKBR3-P), and SKBR3-trastuzumab–
resistant (SKBR3-TtzmR) cells. Blots are representative of three experiments        
                      
 
B. Western blots for SIRT6 and phosphorylated AKT at Ser473(pAKT-Ser473) in  
BT474-PandBT474-TtzmRcells treated with trastuzumab for up to 48 hours. Blot is 
representative, and data in graph are means ± SE abundance of SIRT6 normalized to 
tubulin from three independent experiments 
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 Figure 24: Loss of SIRT6 results in Trastuzumab resistance 
 
C. Cell viability, assessed by relative proliferation by an MTT [3-(4,5-dimethylthiazol-2- 
yl)- 2,5-diphenyltetrazolium bromide] assay, in BT474-TtzmR cells that stably expressed 
SIRT6-WT, SIRT6-S338A, or SIRT6-S338D, and in BT474-P cells transfected with 
luciferase or SIRT6 shRNA, each treated with trastuzumab (10 μg/ml) for 4 days. Blots 
show representative transfection or knockdown, respectively. Data are means ± SE from 
three independent experiments. *P < 0.0001, Student’s t test. 
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 CHAPTER 9:  SUMMARY AND DISCUSSION 
 
Summary 
 Here, we have identified two post translational modifications on SIRT6 that leads 
to its degradation via the proteosome pathway. The degradation of SIRT6 in turn results 
in breast cancer tumorigenesis and resistance to trastuzumab in HER2 overexpressing 
breast cancers. In our proposed model, activated AKT1 interacts with SIRT6 and 
phosphorylates SIRT6 on Ser338. Phosphorylation at this site promotes the interaction 
between SIRT6 and the E3 ligase MDM2, followed by ubiquitination and degradation of 
SIRT6 in a proteosome dependent manner. Loss of SIRT6 in breast cancer, leads to 
enhanced cell proliferation in vitro and aggressive breast tumor growth in vivo in an 
orthotropic mouse model, probably through downregulation of genes involved in 
tumorigenesis. Reconstitution with SIRT6-S338A mutant suppressed breast cancer 
tumorigenesis effectively than the wild type SIRT6, while the SIRT6-S338D mutant has 
no tumor suppressive activity at all. Analysis of human breast cancer patient tissues 
showed that SIRT6 protein expression is indeed downregulated in breast cancer tissues 
compared to the normal breast tissues and patients with high SIRT6 expression have a 
better overall survival than patients with low SIRT6. Also, patients with higher levels of 
phosphorylated SIRT6 have poor survival when compared to those with lower levels. In 
addition, we also found that SIRT6 protein expression was downregulated in cells that 
were resistant to trastuzumab when compared to the sensitive parental cells. Knockdown 
of SIRT6 in the trastuzumab sensitive cells made them resistant to trastuzumab, while 
reconstituition with the SIRT6-S338A mutant rendered these cells sensitive to 
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 trastuzumab to a greater extent that the wild type SIRT6. However, reconstitution with 
SIRT6-S338D mutant did not resensitize the cells to trastuzumab. Thus this data suggests 
that both SIRT6 expression and SIRT6 phosphorylation could be used as biomarkers for 
breast cancer and also for trastuzumab resistance in breast cancer. 
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 Figure 25: Model of AKT1 dependent SIRT6 degradation 
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 Discussion 
 
The histone deacetylase SIRT6 regulates a number of functions including aging, 
inflammation, glucose metabolism, mitochondrial respiration, DNA damage repair etc. 
These processes either directly or indirectly contribute to tumorigenesis. Although the 
role of SIRT6 as a tumor suppressor in a number of cancers has started to unfold, there 
are no clear thoughts on how SIRT6 might be regulated in these cancers. So, we sought 
out to identify novel regulations of SIRT6 in breast cancers and how these regulations 
control breast cancer tumorigenesis. 
In this study, we propose a model in which the histone deacetylase SIRT6 is 
phosphorylated and inhibited by the serine/threonine kinase AKT1. Mechanistically, 
SIRT6 is phosphorylated by AKT1 and targeted for subsequent degradation by the 
MDM2-dependent proteosome degradation pathway (Figure. 25). We have identified 
Ser338 to be the AKT1 phosphorylation site on SIRT6 and this phosphorylation increased 
the interaction between MDM2 and SIRT6 and hence its degradation. Thus this work has 
led to the identification of two novel post translational modifications of SIRT6 that 
affects its protein stability. Independently, the Ser338 site on SIRT6 was identified by 
another group (127), which shows that this phosphorylation is highly conserved and it 
modulates interactions of SIRT6. 
 Prior to our finding that MDM2 is a novel E3 ligase for SIRT6, Ronnebaum et al. 
had identified C terminus of Hsc70-interacting protein (CHIP) as an E3 ligase that 
stabilized SIRT6 through non-canonical ubiquitination (139). But, they had also observed 
canonical ubiquitination of SIRT6 even in the absence of CHIP. This is interesting, as it 
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 is an indication of a possibility for other E3 ligases like MDM2 to ubiquitinate and 
degrade SIRT6. Moreover, recently, ubiquitin peptidase or deubiquitinase, USP10 was 
shown to interact with, deubiquitinate, and stabilize SIRT6 in colon cancer cells (140). 
Also, USP10 deubiquitinates and stabilizes p53, which is a well-known substrate that is 
degraded by MDM2-dependent proteosome pathway. This proposes a similar mechanism 
wherein SIRT6 is destabilized through ubiquitination by MDM2, which could be 
reversed by deubiquitination by USP10. 
To further delineate the significance of SIRT6 phosphorylation with respect to 
breast cancer tumorigenesis, we mutated the serine 338 residue to alanine (SIRT6-
S338A) and to aspartate (SIRT6-S338D) to generate the nonphosphorylatable and the 
phosho-mimic mutants of SIRT6 respectively. We used various in vitro assays and in 
vivo experiments in mice to show that the nonphosphorylatable SIRT6-S338A mutant is 
resistant to MDM2-mediated degradation, is more stable than wild-type SIRT6, and 
promotes stronger suppression of cell proliferation in vitro and tumor growth in vivo in 
mice. SIRT6 phosphorylation also affected the transcription of SIRT6 target genes that 
are involved in promoting tumorigenesis, with some genes affected more significantly 
than the others. The SIRT6-S338A suppressed transcription greater that the WT-SIRT6, 
while the SIRT6-S338D mutant had no inhibitory effect.  
 Our results, together with previously published studies (39, 141-144), further 
strengthen the role of SIRT6 as a tumor suppressor in numerous cancers and how loss of 
SIRT6 is a critical step for the promotion of tumorigenesis. 
Increased AKT activation is also associated with the development of trastuzumab 
resistance in breast tumors overexpressing HER2 (133, 134, 145). Various treatment 
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 alternatives and combination therapies have been designed to overcome this issue of 
resistance, including combining trastuzumab with the SRC inhibitor sarcatinib (146) or 
an AKT inhibitor (147) and, most recently, trastuzumab-DM1 (T-DM1) was developed 
by Genentech,  in which a cytotoxic agent mertansine is linked to the monoclonal 
antibody against HER2 (148). Because, we found that AKT signaling can negatively 
regulate SIRT6, we looked if SIRT6 downregulation could also be associated with 
resistance to trastuzumab. As expected, SIRT6 protein levels were lower in trastuzumab-
resistant cells than in trastuzumab-sensitive cells. When we manipulated SIRT6 
abundance in resistance cells, we were able to modulate its sensitivity to trastuzumab. 
Reconstitution of SIRT6-S338A in the resistant cells, rendered the cells sensitive to 
trastuzumab again to a greater extent compared to the wild type, while the SIRT6-S338D 
mutant had no effect. Thus these results suggest that by manipulating SIRT6 abundance, 
we could modulate the sensitivity to trastuzumab and that the loss of SIRT6 might be one 
of the mechanisms that enable acquired resistance to trastuzumab. This suggests that 
histochemical analysis of SIRT6 expression in breast cancer patients treated with 
trastuzumab might be used as a biomarker to determine drug sensitivity in them. 
 Interestingly, SIRT6 has been shown to activate PARP1 during oxidative 
stress and thus promotes efficient DNA repair (51). PARP is a family of proteins 
consisting of PARP1 and PARP2, and they recruit other DNA repair proteins to the sites 
of DNA damage (149). They play a critical role in repair of DNA through Base Excision 
Repair (BER). This makes PARP effective targets for anti-cancer therapies and there are 
a number of PARP1 inhibitors that are currently in clinical trials. We and others have 
shown that SIRT6 acts as a tumor suppressor in various cancers. But the fact that SIRT6 
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 can activate PARP1, implies the possibility of another role for SIRT6 in tumorigenesis. It 
would be interesting to investigate if SIRT6 also has a role in tumor progression which 
might be context dependent. 
 Also, we have seen that the SIRT6 phosphorylation on Ser338 affects its 
stability and further analysis would have to be done to see if this phosphorylation has any 
effect on the deacetylase activity or ADP-ribosyl transferase activity of SIRT6. 
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 FUTURE DIRECTIONS: 
 
1. To study the relation between SIRT6 and trastuzumab resistance 
 The cell line data showed that SIRT6 protein levels were lower in trastuzumab 
resistant BT474-TtzmR compared to the sensitive BT474-P cells. Also, reexpression of 
SIRT6-S338A mutant in the BT474-TtzmR cells overcame the acquired resistance to 
trastuzumab, more effectively than the SIRT6-WT. We would like to see if these 
phenomenon exist in vivo. To test this, we would perform two independent sets of 
experiments.  
 First experiment would be designed to analyze if SIRT6 is lost when the 
cells become resistant to trastuzumab treatment. Female nude mice would be implanted 
with 0.72 mg, 60-day release 17β-estradiol pellets before inoculating with the appropriate 
cell lines. Tumors would be established by injecting BT474-Parental (BT474-P) cells (5 
× 106) into the mammary fat pads of mice (20 mice per group). Tumor size would be 
measured every 3 days. When the tumor volume reaches about 200 mm3, the mice would 
be randomly distributed into two groups. The experimental group would be treated with  
trastuzumab (10 mg/kg) and the control group with vehicle (IgG) intraperitoneally (i.p.),  
once a week. Two scenarios can be expected from the experimental group- the tumors 
that are sensitive to trastuzumab would shrink, the tumors that are resistant would 
continue growing even under treatment and the tumors which acquire resistance would 
continue to shrink initially, but then starts to grow in the presence of trastuzumab. 
Tumors would be harvested at these different stages and would be stained for SIRT6 and 
phospho SIRT6-Ser338 expression by immunohistochemistry. These results would 
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 indicate if SIRT6 is lost while acquiring resistance to trastuzumab in vivo and if the 
mechanism for loss of SIRT6 is through phosphorylation mediated degradation. 
 In the second set of experiments, we would like to see if SIRT6 phosphorylation 
affects the acquired resistance to trastuzumab. BT474-TtzmR cells which express either 
WT/S33A/S338D SIRT6 would be injected into the mammary fat pads of nude mice, as 
mentioned above and after the tumors reach around 200 mm3 in volume, they would be 
started under trastuzumab treatment and the tumor volumes would then be monitored. 
Based on the cell line data, we would expect the BT474-TtzmR that express the SIRT6-
S33A mutant to be sensitive to trastuzumab and not acquire resistance. 
 
2. Analysis of SIRT6 expression in trastuzumab treated patients 
 Preliminary analysis showed that SIRT6 abundance is reduced in HER2 
overexpressing breast cancer cells that had acquired resistance to trastuzumab when 
compared to the parental sensitive cell lines. Also, reconstitution of the 
nonphosphorylatable SIRT6 mutant in the resistant cells resensitized these cells to 
trastuzumab again. We would like to further investigate the association between SIRT6 
abundance and acquired resistance to trastuzumab in breast cancer patients treated with 
trastuzumab. Immunohistochemical analysis for SIRT6 and phospho SIRT6-S338 in the 
tissues obtained from breast cancer patients at MD Anderson Cancer Center who were 
treated with trastuzumab would be performed. Tissue specimens from patients who are 
sensitive, resistant and who were initially sensitive, but acquired resistance to 
trastuzumab would be analyzed and compared. 
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 3. Identification of kinases responsible for phosphorylation of SIRT6 in Ser303 and 
Ser330 
  Mass spectrometry analysis had identified two other phosphorylation sites on 
SIRT6 under growth factor stimulation, Ser303 and Ser330. We would like to identify the 
kinase(s) that are responsible for phosphorylating SIRT6 on these sites. Preliminary 
analysis of the amino acid sequence of SIRT6 revealed that these two residues lie within 
a CDK consensus phosphorylation motif. The CDK consensus sequence for 
the phosphorylation site in the substrate is [S/T*]PX[K/R], where S/T* is the 
phosphorylated serine or threonine, P is proline, X is any amino acid, K is lysine, and R 
is arginine(150). We would further confirm which CDK(s) phosphorylates SIRT6 on 
Ser303 and (or) Ser330 by performing in vitro kinase assay. The phosphorylation site would 
then be confirmed by mutational analysis of the serine residue(s) to alanine, followed by 
kinase assay. 
 After the successful confirmation of the kinase and the phosphorylation site(s), 
the next step would be the identification of the functional significance of this 
phosphorylation on SIRT6. As CDKs plays a critical role in cell cycle regulation, we 
would like to look at the role of SIRT6 in cell cycle regulation, if any and also the role of 
this phosphorylation with respect to cell cycle.  
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